Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
84 hedge funds and large institutions have $65M invested in Oncternal Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 7 closing their positions.
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
31% more funds holding
Funds holding: 64 → 84 (+20)
21% less capital invested
Capital invested by funds: $82.5M → $65M (-$17.4M)
36% less call options, than puts
Call options by funds: $1.33M | Put options by funds: $2.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.22M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$3M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$2.93M |
| 5 |
Two Sigma Investments
New York
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$5.62M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.69M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.18M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.16M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.65M |
ONCT Hedge Fund Activity: Q2 2021 in Review
84 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2021, worth a combined $65M — down 21% from $82.5M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ONCT positions and 7 closed out — a net gain of 20 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $12.6M. The largest seller was Invesco, cutting an estimated $5.62M.
- 84 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2021, up from 64 in Q1 2021.
- Funds reported $65M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2021, down 21% quarter-over-quarter.
- 27 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2021 and 7 closed out, a net change of +20 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $12.6M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2021 was Invesco, an estimated $5.62M sold.
Based on aggregated 13F filings for Q2 2021.